Indoxyl sulfate and atherosclerotic risk factors in hemodialysis patients

American Journal of Nephrology

Volumn 27, Issue 1, 2007, Pages 30-35

  Taki, Kentaro ^a   Tsuruta, Yoshinari ^b   Niwa, Toshimitsu ^a  

^a NAGOYA UNIVERSITY HOSPITAL   (Japan)

^b Meiyo Clinic   (Japan)

Author keywords

Atherosclerosis; Hemodialysis; High density lipoprotein cholesterol; Indoxyl sulfate; Pentosidine

Indexed keywords

BIOLOGICAL MARKER; CALCIUM; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDICAN; PENTOSIDINE; PHOSPHATE;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD LEVEL; CALCIUM BLOOD LEVEL; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN METABOLISM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARGININE; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CREATININE; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INCIDENCE; INDICAN; LYSINE; MALE; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; RENAL DIALYSIS; UREMIA;

EID: 33847668826     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000098542     Document Type: Article

References (33)

1. Niwa T, Ise M: Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J Lab Clin Med 1994;124:96-104.
2. Niwa T, Nomura T, Sugiyama S, Miyazaki T, Tsukushi S, Tsutsui S: The protein metabolite hypothesis, a model for the progression of renal failure: an oral sorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kidney Int 1997;52(suppl 62):S23-S28.
3. Miyazaki T, Ise M, Seo H, Niwa T: Indoxyl sulfate increases the gene expression of TGF-β1, TIMP-1 and pro-alpha 1(I) collagen in uremic rat kidneys. Kidney Int Suppl 1997;62:S15-S22.
4. Miyazaki T, Aoyama I, Ise M, Seo H, Niwa T: An oral sorbent reduces overload of indoxyl sulfate and gene expression of TGF-β1 in uremic rat kidneys. Nephrol Dial Transplant 2000;15:1773-1781.
5. Motojima M, Hosokawa A, Yamato H, Muraki T, Yoshioka T: Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-κB and free radical in proximal tubular cells. Kidney Int 2003;63:1671-1680.
6. Enomoto A, Takeda M, Tojo A, Sekine T, Cha SH, Khamdang S, Takayama F, Aoyama I, Nakamura S, Endou H, Niwa T: Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity. J Am Soc Nephrol 2002;13:1711-1720.
7. Dou L, Bertrand E, Cerini C, Faure V, Sampol J, Vanholder R, Berland Y, Brunet P: The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int 2004;65:442-451.
8. Yamamoto H, Tsuruoka S, Ioka T, Ando H, Ito C, Akimoto T, Fujimura A, Asano Y, Kusano E: Indoxyl sulfate stimulates proliferation of rat vascular smooth muscle cells. Kidney Int 2006;69:1780-1785.
9. Miyata T, Ueda Y, Yamada Y, Izuhara Y, Wada T, Jadoul M, Saito A, Kurokawa K, van Ypersele de Strihou C: Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product. carbonyl stress in uremia. J Am Soc Nephrol 1998;9:2349-2356.
10. Kaul N, Siveski-Iliskovic N, Hill M, Slezak J, Singal PK: Free radicals and the heart. J Pharmacol Toxicol Methods 1993;30:55-67.
11. Schwedler S, Schinzel R, Vaith P, Wanner C: Inflammation and advanced glycation end products in uremia. simple coexistence, potentiation or causal relationship? Kidney Int 2001;59(suppl 78):S32-S36.
12. Brownlee M: Advanced protein glycosylation in diabetes and aging. Annu Rev Med 1995;46:223-234.
13. Ahmed MU, Thorpe SR, Baynes JW: Identification of Nε- carboxymethyllysine as a degradation product of fructoselysine in glycated protein. J Biol Chem 1986;261:4889-4894.
14. Sell DR, Monnier VM: Structure elucidation of a senescence cross-link from human extracellular matrix. J Biol Chem 1989;264:21597-21602.
15. Miyata T, Ishikawa S, Asahi K, Inagi R, Suzuki D, Horie K, Tatsumi K, Kurokawa K: 2-Isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide (OPB-9195) treatment inhibits the development of intimal thickening after balloon injury of rat carotid artery: role of glycoxidation and lipoxidation reactions in vascular tissue damage. FEBS Lett 1999;445:202-206
16. Kitauchi T, Yoshida K, Yoneda T, Saka T, Yoshikawa M, Ozono S, Hirao Y: Association between pentosidine and arteriosclerosis in patients receiving hemodialysis. Clin Exp Nephrol 2004;8:48-53
17. Ohishi N, Ohkawa H, Miike A, Tatano T, Yagi K: A new assay method for lipid peroxides using a methylene blue derivative. Biochem Int 1985;10:205-211.
18. Yagi K: A simple fluorometric assay for lipoperoxide in blood plasma. Biochem Med 1976;15:212-216.
19. Vester B, Rasmussen K: High performance liquid chromatography method for rapid and accurate determination of homocysteine in plasma and serum. Eur J Clin Chem Clin Biochem 1991;29:549-554.
20. Niwa T, Takeda N, Tatematsu A, Maeda K: Accumulation of indoxyl sulfate, an inhibitor of drug-binding, in uremic serum as demonstrated by internal-surface reversed-phase liquid chromatography. Clin Chem 1988;34:2264-2267.
21. Niwa T. Uremic Toxicity. Indoxyl sulfate; in Massry SG, Glassock RJ (eds): Textbook of Nephrology. Baltimore, Williams & Wilkins, 2001, pp 1269-1272.
22. Niwa T, Ise M, Miyazaki T: Progression of glomerular sclerosis in experimental uremic rats by administration of indole, a precursor of indoxyl sulfate. Am J Nephrol 1994;14:207-212.
23. Vanhoutte PM: Endothelial dysfunction and atherosclerosis. Eur Heart J 1997;18(suppl E):E19-E23.
24. Sattar N, Petrie JR, Jaap AJ: The atherogenic lipoprotein phenotype and vascular endothelial dysfunction. Atherosclerosis 1998;138:229-235.
25. Toikka JO, Ahotupa M, Viikari JS, Niinikoski H, Taskinen M, Irjala K, Hartiala JJ, Raitakari OT: Constantly low HDL-cholesterol concentration relates to endothelial dysfunction and increased in vivo LDL-oxidation in healthy young men. Atherosclerosis 1999;147:133-138.
26. Nofer JR, Kehrel B, Fobker M, Levkau B, Assmann G, von Eckardstein A: HDL and arteriosclerosis. beyond reverse cholesterol transport. Atherosclerosis 2002;161:1-16.
27. Choudhury RP, Rong JX, Trogan E, Elmalem VI, Dansky HM, Breslow JL, Witztum JL, Fallon JT, Fisher EA: High-density lipoproteins retard the progression of atherosclerosis and favorably remodel lesions without suppressing indices of inflammation or oxidation. Arterioscler Thromb Vasc Biol 2004;24:1904-1909.
28. Durak I, Akyol O, Basesme E, Canbolat O, Kavutcu M: Reduced erythrocyte defense mechanisms against free radical toxicity in patients with chronic renal failure. Nephron 1994;66:76-80.
29. Mimic-Oka J, Simic T, Djukanovic L, Reljic Z, Davicevic Z: Alteration in plasma antioxidant capacity in various degrees of chronic renal failure. Clin Nephrol 1999;51:233-241.
30. Markert M, Heierli C, Kuwahara T, Frei J, Wauters JP: Dialyzed polymorphonuclear neutrophil oxidative metabolism during hemodialysis. A comparative study with 5 new and reused membranes. Clin Nephrol 1988;29:129-136.
31. Dasgupta A, Hussain S, Ahmad S: Increased lipid peroxidation in patients on maintenance hemodialysis. Nephron 1992;60:56-59.
32. Parthasarathy S, Barnett J, Fong LG: High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1990;1044:275-283.
33. Navab M, Hama SY, Anantharamaiah GM, Hassan K, Hough GP, Watson AD, Reddy ST, Sevanian A, Fonarow GC, Fogelman AM: Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res 2000;41:1495-1508.